DSIP Peptide: Status, Evidence and Sellers

DSIP, short for delta sleep-inducing peptide, is a chain of nine amino acids that a group in Basel isolated in 1977 from the blood of rabbits [1]. It was named for its first reported effect: infused into rabbits' brains, it increased the slow-wave, or delta, pattern on brain recordings [7]. FDA's records use its official name, emideltide [5].

It is sold today as a sleep aid, and its name does most of the selling. A 2006 review by sleep researchers concluded that the case for DSIP as a sleep factor is extremely poorly documented and still weak, and noted that no gene, precursor protein or receptor for it has been isolated [1].

DSIP has no FDA approval and is not one of the six peptides in the October 28, 2026 HHS policy. FDA lists it among withdrawn compounding nominations, saying it lacks the information to know whether it would harm people [5].

Most drugs work by binding a specific receptor. For DSIP none has been found, so there is no known route from the molecule to the effect in its name [1]. DSIP-like material has been detected in the hypothalamus of many animal species, and researchers have measured a wide range of effects in cells and animals, but those results have not added up to a defined role in sleep [1].

The same review reported that certain lab-made variants of DSIP, but not DSIP itself, promoted slow-wave sleep in rabbits and rats, and proposed that a related natural peptide might explain what early researchers saw [1].

Human trials took place mostly in the 1980s and early 1990s and were small. A 1987 placebo-controlled study in 14 middle-aged people with severe chronic insomnia reported that seven nights of DSIP substantially improved night sleep and daytime alertness [2]. Two other double-blind studies were less encouraging. One gave insomniacs 25 nmol per kg intravenously over four nights and found that the apparent gains were already present on baseline nights, concluding the improvement was of little clinical significance [3]. The other, in 16 chronic insomniacs, found small objective gains that may have reflected a chance change in the placebo group and no change in how well people felt they slept, and concluded DSIP was not likely to be of major benefit [4].

No trial we found tested it as an injection under the skin, and none is large or recent. Grade C: a few small controlled studies with mixed results and no known mechanism. Our evidence review covers the missing receptor in more depth.

No dose of DSIP is approved. The trials we read gave it intravenously, at 25 nmol per kg in two of them [3] [4]. Those regimens were given in sleep laboratories, by vein, and do not translate into the injection protocols sellers quote, which this page does not repeat.

The small trials did not report serious problems, but they were short and were not designed to find uncommon harms. FDA's assessment is that it has not identified safety information for the route proposed for compounding and lacks enough information to know whether DSIP would harm people. Its safety-risk page also flags the possibility of an immune reaction to the peptide and of impurities from manufacture [5].

Long-lasting insomnia is worth raising with a doctor, since it can signal conditions such as sleep apnea or depression and has treatments with much stronger evidence behind them.

DSIP is not named on the World Anti-Doping Agency's 2026 Prohibited List. The list's S0 class covers substances with no current approval from any government health authority for human use [6], so athletes should check with their anti-doping organization.